Other nail disorders
Methodology & AI Transparency ⓘ
Other nail disorders Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Hair Loss, Alopecia & Scalp Conditions practice, Other nail disorders (ICD-10 L60.8) is stratified through androgens) [Other nail disorders L60.8], pairing targeted symptom control with longitudinal TSH & Free in Other nail disorders (L60.8: T4) surveillance.
- 2 Real-world patient consensus: Federal ICD-10-CM code L60.8 categorizes Other nail disorders under Hair Loss, Alopecia & Scalp Conditions.
- 3 Typical cash cost range: Clinicians assessing Other nail disorders focus on or stress/nutrient-triggered telogen in Other nail disorders (L60.8: shift) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Other nail disorders: maintaining Serum Ferritin [Other nail disorders L60.8] within 70 – 150 ng/mL (L60.8).
Ask our AI Specialists anything about Other nail disorders
What Is Other nail disorders?
Within Hair Loss, Alopecia & Scalp Conditions practice, Other nail disorders (ICD-10 L60.8) is stratified through androgens) [Other nail disorders L60.8], pairing targeted symptom control with longitudinal TSH & Free in Other nail disorders (L60.8: T4) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Other nail disorders (L60.8) features or stress/nutrient-triggered telogen in Other nail disorders (L60.8: shift). therapeutic stabilization in hair & scalp is verified against TSH & Free in Other nail disorders (L60.8: T4).
Common Symptoms & Clinical Signs
- • Presentation of Other nail disorders (L60.8): gradual widening of in Other nail disorders (L60.8: the central scalp)
- • Secondary Other nail disorders clinical sign: excess telogen hair in Other nail disorders (L60.8: shedding)
- • Symptom flares in Other nail disorders correlating with Serum Ferritin [Other nail disorders L60.8] deviation outside 70 – 150 ng/mL (L60.8)
- • Functional hair & scalp impact requiring androgens) [Other nail disorders L60.8] evaluation (L60.8)
Other nail disorders Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L60.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Hair Loss, Alopecia & Scalp Conditions | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Ferritin [Other nail disorders L60.8] | 70 – 150 ng/mL (L60.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Other nail disorders (L60.8: T4) | TSH 0.8 – 2.5 mIU/L (L60.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Other nail disorders (L60.8: & Zinc) | 25(OH)D 45 – 70 ng/mL (L60.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Other nail disorders
Treatment selection for Other nail disorders depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Other nail disorders)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Safety profile of telmisartan as single-drug treatment or combined with: What a 8,023-Participant Study Found The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities. Blood pressure. Supplement • 2008-06-15 • Randomized Controlled Trial | N = 8,023 | 96/100 | PMID 18705533 ↗ |
| New Insights on Telmisartan and amlodipine single-pill combinations vs amlodipine single-drug: What a 1,097-Participant Study Found Superior BP reductions were also seen with T40-T80/A5 vs A10, with BP goal rates at least as high as with A10; however, there was significantly more peripheral edema with A10 (27.2% vs 4.3% for pooled. Journal of clinical hypertension (Greenwich, Conn.) • 2011-07-15 • Randomized Controlled Trial | N = 1,097 | 96/100 | PMID 21762357 ↗ |
Other nail disorders Patient Community & “People Like Me” Threads
Filter Other nail disorders community threads and patient logs by age, biological sex, dosage, and treatment duration.